Truist Securities Reiterates Hold on Quest Diagnostics, Maintains $145 Price Target
Portfolio Pulse from Benzinga Newsdesk
Truist Securities analyst David Macdonald has reiterated a Hold rating on Quest Diagnostics (NYSE:DGX) and maintained a price target of $145.

March 20, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Truist Securities maintains a Hold rating and a $145 price target on Quest Diagnostics, as reiterated by analyst David Macdonald.
The reiteration of the Hold rating and maintenance of the price target by a notable analyst suggests a neutral short-term impact on Quest Diagnostics' stock. The analyst's view likely reflects a balanced outlook on the company's current valuation and future prospects, without significant new information to drive a change in stock price direction.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 90